InvestmentApr 15, 2026, 04:03 PM
Traws Pharma Secures Up to $60M Private Financing
AI Summary
Traws Pharma completed a private financing of up to $60 million, including an initial $10 million, which is expected to fund operations into Q1 2027. This capital will support the advancement of its lead investigational program, tivoxavir marboxil (TXM), towards a Phase 2a human influenza challenge trial. The company also reported positive topline Phase 2a data for Ratutrelvir in COVID patients and is engaging with the FDA to resolve a clinical hold for TXM in the U.S.
Key Highlights
- Secured up to $60M in private financing, with $10M upfront.
- Financing extends operations into Q1 2027.
- TXM advancing to Phase 2a human influenza challenge trial.
- Ratutrelvir Phase 2a data shows differentiated profile in COVID.
- Sold 5,982,919 shares at $1.6730 each in financing.